Ascentage Pharma Group International

AAPG · HONG

$15.44+$0.52 (+3.49%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $14.92

AAPG analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $26.01 (+68.4% upside)

Low: $25.75
Now: $15.44
High: $26.77

Upgrades and downgrades

The latest rating actions, newest first

AAPG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
William Blair	Oct 16, 2026	Initiates	Outperform	—	57%
Citigroup	Oct 14, 2026	Initiates	Buy	$46.00	43%
Citizens	Oct 13, 2026	Initiates	Market Outperform	$35.00	21%
JP Morgan	Oct 8, 2026	Maintains	Overweight	$46.00 → $33.00	41%
BTIG	Aug 21, 2026	Maintains	Buy	$48.00	56%
BTIG	Jun 15, 2026	Maintains	Buy	$48.00	56%
B. Riley Securities	Jun 10, 2026	Initiates	Buy	$45.00	47%
BTIG	Apr 13, 2026	Maintains	Buy	$48.00	56%
BTIG	Mar 26, 2026	Maintains	Buy	$48.00	56%
BTIG	Mar 12, 2026	Initiates	Buy	$48.00	56%

The case for and against

Updated Oct 23, 2026

Bull case

Ascentage Pharma Group is supported by a differentiated apoptosis-focused pipeline that pairs lisaftoclax’s improved PK/PD, shorter half-life, lower drug-drug interactions, and lower severe cytopenia burden with olverembatinib’s proven activity in later-line, refractory CML and T315I disease. Its outlook is strengthened by de-risking from approvals in China, a Takeda exclusive option that could unlock up to approximately $1.2 billion in development, commercial, and sales milestones plus 12% to 19% royalties, and a broad clinical footprint spanning the United States and Mainland China. With two de-risked commercial anchors, 2027 Phase 3 readouts in MDS and CML, and recent data showing lisaftoclax ORR of 76.7% in r/r AML and 80% in TN HR-MDS, the company has multiple near-term catalysts and meaningful upside optionality.

Bear case

Ascentage Pharma Group is viewed negatively because its core pipeline faces substantial clinical and commercial uncertainty, with venetoclax’s failure to improve overall survival in the Phase 3 VERONA study underscoring the risk that better response rates may not convert into durable benefit. Its lead assets also confront intense competition and safety concerns: APG-3288 must match or beat stronger BTK degrader data, while lisaftoclax could still fail overall survival or face uptake limits from cytopenias, infections, and low-cost generic hypomethylating agents. The company remains a clinical-stage biotech with seven drug candidates, implying ongoing regulatory, financing, and dilution risk, especially as it may need additional equity funding and has not yet established broad commercial differentiation in the United States and Mainland China.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.